Roquefort Therapeutics (LON:COIL) Trading Up 15% – What’s Next?

Roquefort Therapeutics plc (LON:COIL)’s stock price shot up 15% during mid-day trading on Wednesday . The company traded as high as GBX 9.78 and last traded at GBX 9.78. 888,871 shares were traded during trading, an increase of 349% from the average session volume of 197,768 shares. The stock had previously closed at GBX 8.50.

Roquefort Therapeutics Stock Up 17.6%

The business’s 50 day simple moving average is GBX 10.60 and its 200-day simple moving average is GBX 14.39. The company has a market cap of £16.37 million, a price-to-earnings ratio of -15.87 and a beta of 0.05. The company has a debt-to-equity ratio of 8.07, a quick ratio of 3.07 and a current ratio of 2.80.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.